ArticleJournal of clinical practice and research2025
The Effects of Carbohydrate Counting Over Glycometabolic Control in Patients Diagnosed with Type 1 Diabetes Mellitus.
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Advanced carbohydrate counting (CC), a nutritional intervention that adjusts insulin based on the estimated carbohydrate content of meals, has shown inconsistent effects on glycometabolic control. This study aimed to evaluate the long-term efficacy of advanced CC in patients with type 1 diabetes mellitus (DM) and assess adherence and consistency rates. Materials and Methods: Adult patients diagnosed with type 1 DM who applied multiple dose insulin therapy were included. Data from patients who completed advanced CC training and practiced it for at least 3 months were retrospectively reviewed. Baseline demographic data, as well as BMI, HbA1c, lipid profile, daily insulin doses, meal frequency, hospital visits, and chronic complication rates, were evaluated before and after CC. Results: Twenty-five patients (mean± SD age: 22.6±7.7 years, 68% female) were included. The duration of CC was a median (IQR) of 40 (12-75) months. HbA1c levels significantly improved (p=0.023), while BMIs and lipid parameters remained similar. Four patients experienced diabetic ketoacidosis in the year before starting CC and none during follow-up (p=0.046). None of the patients had new-onset diabetic complications during CC. The adherence rate was 69.5%, and the discontinuation rate was 32%. The primary reason for discontinuation was the difficulty in implementing the method daily. Conclusion: Advanced CC is effective for improving glycemic control in patients with type 1 DM, with effects that last for a long time. Consistency may be hindered for some patients by difficulties integrating it into their daily life. Dietary and lifestyle advice should be individualized in patients with type 1 DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.